Linical Co., Ltd. (JP:2183)
:2183
2183 Stock Chart & Stats
¥293.00
-¥1.00(-0.28%)
At close: 4:00 PM EST
¥293.00
-¥1.00(-0.28%)
Day’s Range― - ―
52-Week Range¥258.00 - ¥363.00
Previous CloseN/A
Volume36.50K
Average Volume (3M)14.99K
Market Cap
¥6.19B
Enterprise Value¥3.39B
Total Cash (Recent Filing)¥5.53B
Total Debt (Recent Filing)¥2.22B
Price to Earnings (P/E)―
Beta0.64
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.44%
Share Statistics
EPS (TTM)-27.61
Shares Outstanding24,740,000
10 Day Avg. Volume18,600
30 Day Avg. Volume14,993
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)0.69
P/FCF Ratio12.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Fee‑based, Diversified CRO ModelA fee-based, project and contract-driven CRO model creates durable revenue streams tied to client pipelines and multi-phase studies. Diverse service lines (operations, data, medical writing, regulatory) reduce single-service exposure and support repeat business and cross‑sell over multiple quarters.
Strong Balance Sheet LiquidityModerate leverage and a healthy equity ratio provide a resilient capital base to withstand project timing variability inherent in CRO work. Negative net debt and strong liquidity preserve financial flexibility for bid support, staffing and selective investment during multi‑quarter recovery periods.
Positive Operating Cash GenerationPositive operating cash flow despite accounting losses shows core service operations generate cash, enabling the company to fund working capital and project ramp costs internally. This supports continuity of operations and lowers reliance on external financing over several quarters.
Bears Say
Revenue Decline And Inconsistent GrowthDeclining top-line and inconsistent revenue trends reduce scale benefits and make fixed-cost absorption harder for a labor‑intensive CRO. Over multiple quarters this can pressure pricing, limit ability to invest in talent and systems, and weaken competitive positioning versus growing peers.
Negative Net Income And Margin DeteriorationSustained negative profitability and eroding operating margins undermine internal funding for growth and raise the risk of margin compression in contract renewals. Persistent losses can erode investor and client confidence and limit resources for technology and quality investments critical in CRO services.
Declining Free Cash Flow TrendA downward trend in free cash flow constrains capacity to hire specialized staff, invest in digital platforms, or absorb delayed client payments. If the decline continues over several quarters it may force tradeoffs between reinvestment and cost cutting, hindering long‑term competitiveness.
Linical Co., Ltd. News
2183 FAQ
What was Linical Co., Ltd.’s price range in the past 12 months?
Linical Co., Ltd. lowest stock price was ¥258.00 and its highest was ¥363.00 in the past 12 months.
What is Linical Co., Ltd.’s market cap?
Linical Co., Ltd.’s market cap is ¥6.19B.
When is Linical Co., Ltd.’s upcoming earnings report date?
Linical Co., Ltd.’s upcoming earnings report date is May 18, 2026 which is in 52 days.
How were Linical Co., Ltd.’s earnings last quarter?
Linical Co., Ltd. released its earnings results on Feb 13, 2026. The company reported -¥27.61 earnings per share for the quarter, missing the consensus estimate of N/A by -¥27.61.
Is Linical Co., Ltd. overvalued?
According to Wall Street analysts Linical Co., Ltd.’s price is currently Overvalued.
Does Linical Co., Ltd. pay dividends?
Linical Co., Ltd. pays a Annually dividend of ¥16 which represents an annual dividend yield of 5.44%. See more information on Linical Co., Ltd. dividends here
What is Linical Co., Ltd.’s EPS estimate?
Linical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Linical Co., Ltd. have?
Linical Co., Ltd. has 24,740,000 shares outstanding.
What happened to Linical Co., Ltd.’s price movement after its last earnings report?
Linical Co., Ltd. reported an EPS of -¥27.61 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.208%.
Which hedge fund is a major shareholder of Linical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2183
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Linical Co., Ltd.
Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.
Technical Analysis
Trans Genic Inc.
―
MEDINET Co., Ltd.
―
TMS Co., Ltd.
―
Takara Bio Inc.
―
ReproCELL Inc.
―